Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 676 to 700 of 881

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Nivolumab in combination with ipilimumab for treating advanced melanoma	TA400	27 July 2016	27 July 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen	TA259	27 June 2012	27 July 2016
Adalimumab for treating moderate to severe hidradenitis suppurativa	TA392	22 June 2016	22 June 2016
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	TA393	22 June 2016	22 June 2016
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	TA394	22 June 2016	22 June 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	TA395	22 June 2016	22 June 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma	TA396	22 June 2016	22 June 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes	TA390	25 May 2016	25 May 2016
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	TA388	27 April 2016	27 April 2016
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	TA389	27 April 2016	27 April 2016
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis	TA386	23 March 2016	23 March 2016
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)	TA23	26 April 2001	3 March 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia	TA385	24 February 2016	24 February 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma	TA384	18 February 2016	18 February 2016
TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis	TA383	1 February 2016	1 February 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	TA377	27 January 2016	27 January 2016
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy	TA378	27 January 2016	27 January 2016
Nintedanib for treating idiopathic pulmonary fibrosis	TA379	27 January 2016	27 January 2016
Panobinostat for treating multiple myeloma after at least 2 previous treatments	TA380	27 January 2016	27 January 2016
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)	TA382	27 January 2016	27 January 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	TA375	26 January 2016	26 January 2016
Guidance on the use of imatinib for chronic myeloid leukaemia	TA70	22 October 2003	21 January 2016
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	TA373	16 December 2015	16 December 2015
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy	TA374	16 December 2015	16 December 2015
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	TA369	16 December 2015	16 December 2015

Results per page

10
25
50
All